Mark M Staveski

US Patent:

6372752, Apr 16, 2002

Filed:

Feb 7, 2000

Appl. No.:

09/499183

Inventors:

Mark M. Staveski - Taunton MA
Scott F. Sneddon - Salem MA
Christopher Yee - Needham MA
Andrew Janjigian - Cambridge MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31505

US Classification:

514273, 514249, 514256, 544331, 544333, 544353

Abstract:

The invention relates to compounds which inhibit the Mycobacterial enoyl-ACP reductase required for cell wall biosynthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of use of these compounds for treating a bacterial infection in a patient.

US Patent:

7186725, Mar 6, 2007

Filed:

Dec 23, 2003

Appl. No.:

10/746034

Inventors:

Mark M. Staveski - Taunton MA, US
Robert J. Miller - E. Bridgewater MA, US
Sharon R. Nahill - Belmont MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K 31/497
A61K 31/445
C07D 239/02
C07D 211/56

US Classification:

51425401, 514326, 514256, 544333, 544335, 546210

Abstract:

The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comprise disubstituted ureas of Formulas I, II, III or IV:R—NH—CO—NH-Q-RFormula I:Et-NH—CO—NH-Q-R:  Formula (II)Et-NH—CO—NH—(CH)—NRR:  Formula (III)MeN—(CH)—NH—CO—NH-Q-R.   Formula (IV).

US Patent:

20040044075, Mar 4, 2004

Filed:

May 29, 2003

Appl. No.:

10/448447

Inventors:

Mark Staveski - Taunton MA, US
Scott Sneddon - Salem MA, US

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

A61K031/24

US Classification:

514/540000

Abstract:

Disclosed herein is a compound represented by Structural Formula (I): Ris a substituted or unsubstituted aryl group or alkyl group; Ris a substituted or unsubstituted aryl group or cycloalkyl group; Ar is a substituted or unsubstituted aryl group; X is a —CH—, —O—, —S— or —CO—; m is an integer from zero to two; n is an integer from 0-2 when X is —O—, —S— and 1-2 when X is —CH— or —CO—. Also disclosed are methods of inhibiting kallikrein activity or urokinase activity in subject in need of such inhibition by administering a compound represented by Structural Formula (I).

US Patent:

20070254894, Nov 1, 2007

Filed:

Jan 9, 2007

Appl. No.:

11/651406

Inventors:

John Kane - Maynard MA, US
Bradford Hirth - Littleton MA, US
Christopher Yee - Needham MA, US
Mark Staveski - Taunton MA, US
Hans-Peter Biemann - Cambridge MA, US
Marko Pregel - Arlington MA, US

International Classification:

A61K 31/4709
A61K 31/497
A61P 9/00
C07D 215/38
C07D 243/08
C07D 401/14
C07D 413/14

US Classification:

514253060, 514314000, 540575000, 544128000, 544238000, 544353000, 544363000, 546171000

Abstract:

Disclosed herein are angiogenesis inhibitors represented by formula (I) or formula (II): The variables for formulas (I) and (II) are defined herein.

US Patent:

53548531, Oct 11, 1994

Filed:

Mar 12, 1993

Appl. No.:

8/030793

Inventors:

Mark M. Staveski - Sharon MA
Barbara Y. F. Wan - Tewksbury MA
Alan E. Walts - Topsfield MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C12P 1944
C07H 1500
C07G 300

US Classification:

536 171

Abstract:

Novel phospholipid-saccharide conjugates are produced by the reaction of a phospholipid derivative and an activated saccharide. The resulting conjugates can be used to make liposomes which are target-specific or resistant to degradation in vivo.